Barclays raised the firm’s price target on DexCom (DXCM) to $93 from $90 and keeps an Equal Weight rating on the shares. The firm made “elatively minor changes” to its model to reflect the company’s Q1 results and revised 2025 guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: